Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Tirabrutinib in B-cell Malignancies
NCT02457559Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of tirabrutinib in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) (12 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events at 61 months and Percentage of Participants Who Experienced Treatment-Emergent Marked Laboratory Abnormalities at 61 months. Started Sep 2015; status: completed.
02
Drugs
tirabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02457559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457559.